Pyrrole derivatives as P2Y12 antagonists

Details Pyrrole derivatives as P2Y12 antagonists Pyrrole derivatives as P2Y12 antagonists

2011-03-22

2011-03-22

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S254010, C546S208000, C544S364000, C544S372000

Reexamination Certificate

active

07910576

ABSTRACT:
The present invention relates to compounds of the formula I,in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

REFERENCES:
patent: 3458515 (1969-07-01), Archibald et al.
patent: 2002/0061892 (2002-05-01), Wang et al.
patent: 2003/0119817 (2003-06-01), Mehta et al.
patent: 2006/0148806 (2006-07-01), Watanuki et al.
patent: 01778801 (2006-05-01), None
patent: WO 02/098856 (2002-12-01), None
patent: WO 2004/052366 (2004-06-01), None
patent: WO 2005/009971 (2005-02-01), None
patent: WO 2005/073203 (2005-08-01), None
patent: WO 2006/077851 (2006-07-01), None
patent: WO 2007/103456 (2007-09-01), None
Takasaki et al, Molecular Cloning of the Platelet P2TAC ADP Receptor: Pharmacological Comparison with Another ADP Receptor, the P2Y1 Receptor, Mol. Pharmacol. 2001 (60) pp. 432-439.
Andre et al, P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injhured arteries, J Clin. Inv. 2003 (112) 3 pp. 398-406.
Dangelmaier et al, Potentiation of Thromboxane A2-induced Platelet Secretion by Gi Signaling through the Phosphoinositide-3 Kinase Pathway, Thromb. Haemost. 2001 (85) pp. 341-348.
Gachet, ADP Receptors of Platelets and their Inhibition, Thromb. Haemost. 2001 (86) pp. 222-232.
Herbert et al, Inhibitory Effect of Clopidrogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits, Arteroscl. and Thromb. 1993 (13) 9 pp. 1171-1179.
Khanna Ish K et al., 1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents, J. Med. Chem., 1997, vol. 40, pp. 1634-1647.
Kunapuli et al, ADP Receptors-Targets for Developing Antithrombotic Agents, Current Pharma. Design, 2003 (9) pp. 2303-2316.
Maffrand et al, ADP Plays a Key Role in Thrombogenesis in Rats, Thrombosis and Haemostasis 1988 (59) 2 pp. 225-230.
Savi et al, Identification and Biological Activity of the Active Metabolite of Clopidogrel, Thromb. Haemost. 2000 (84) pp. 891-896.
Stetter, Die katalysierte Addition von Aldehyden an aktivierte Doppelbindungen—lin neues Syntheseprinzip Angew. Chemie 1976 (21) pp. 695-736.
Storey, The P2Y12 receptor as a therapeutic target in cardiovascular disease, Platelets, 2001 (12) pp. 197-209.

Affiliated with

Also associated with

Rating

Pyrrole derivatives as P2Y12 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrole derivatives as P2Y12 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole derivatives as P2Y12 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2664436